Remove 2030 Remove Licensing Remove Pharmacokinetics
article thumbnail

Donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline

The Pharma Data

Additionally, pharmacokinetic/pharmacodynamic modeling showed that greater relative amyloid plaque clearance was correlated with greater clinical benefit. Lilly plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year.

Disease 52
article thumbnail

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

.” The arrangement is part of Lilly ‘s philanthropic efforts and supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

article thumbnail

Making a “Miracle” HIV Medicine

Codon

Because of PEPFAR’s effectiveness, the United Nations (UN) set an ambitious goal in 2022 to end HIV transmission and eliminate AIDS-related deaths by 2030. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates. Half of the participants received lenacapavir, and the other half an injectable placebo.